

AL CARR
Legislative District 18
Montgomery County

Health and Government Operations
Committee

Subcommittees

Insurance and Pharmaceuticals
Health Occupations and
Long-Term Care

The Maryland House of Delegates
ANNAPOLIS, MARYLAND 21401

The Maryland House of Delegates
6 Bladen Street, Room 222
Annapolis, Maryland 21401
410-841-3638 · 301-858-3638
800-492-7122 Ext. 3638
Fax 410-841-3053 · 301-858-3053
Alfred.Carr@house.state.md.us

Sponsor Testimony in SUPPORT of HB 820
Health Insurance - Pediatric Autoimmune Neuropsychiatric Disorders -
Modification of Coverage Requirements

February 24, 2022

House Bill 820 expands the treatment options for PANDAS or PANS, autoimmune diseases that affect children.

Coverage of PANDAS/PANS treatment has been the subject of a number of bills that have been considered in recent years by the Health and Government Operations Committee. HB 820 builds on the landmark Chapter 560 of 2020.

It is primarily a corrective bill to remove amendment language that was added to the original legislation that passed in the last days of our abbreviated session that year.

The bill removes language that explicitly excludes one brand name medication Rituxin from coverage for the treatment of PANDAS or PANS.

Rituxin has increasingly been demonstrated to be effective in the treatment of autoimmune conditions like PANDAS and PANS.

The language in current law restricts just this one single medication, creating an arbitrary limitation in treatment, and this corrective bill would give patients and practitioners access to the full toolbox of treatments for these conditions.

I respectfully ask for a favorable report.